ライフサイエンスコーパス: persistent atrial fibrillation

1 rhythm in patients with both paroxysmal and persistent atrial fibrillation.

2 cardia, as well as an important substrate of persistent atrial fibrillation.

3 ients underwent pulmonary vein isolation for persistent atrial fibrillation.

4 major pathophysiological mechanism in human persistent atrial fibrillation.

5 ure, coronary disease, renal impairment, and persistent atrial fibrillation.

6 CTs reporting clinical outcomes after CA for persistent atrial fibrillation.

7 nd non-RCTs to assess the efficacy of CA for persistent atrial fibrillation.

8 million in European Union have paroxysmal or persistent atrial fibrillation.

9 went LA mapping before catheter ablation for persistent atrial fibrillation.

10 The primary end point was time to persistent atrial fibrillation.

11 dergoing pulmonary vein antrum isolation for persistent atrial fibrillation.

12 ysiologically relevant heart rate control in persistent atrial fibrillation.

13 ; 72%) or short-standing (<3-month duration) persistent atrial fibrillation (14 of 50 patients; 28%)

14 Of 71 patients with paroxysmal or persistent atrial fibrillation, 22 had progression to pe

15 age, 61+/-10 years) with paroxysmal (550) or persistent atrial fibrillation (583).

16 mplication rates, and similarly low rates of persistent atrial fibrillation 60 days after onset.

17 er (72 versus 74 years), more likely to have persistent atrial fibrillation (83.0% versus 77.6%), and

18 A) electric isolation is reported to improve persistent atrial fibrillation (AF) ablation outcomes.

19 performance in patients with paroxysmal and persistent atrial fibrillation (AF) and controls in sinu

20 servicing the increased energy demand during persistent atrial fibrillation (AF) and to ascertain whe

21 anisms responsible for perpetuation of human persistent atrial fibrillation (AF) are controversial an

22 Long-term success rates using ablation for persistent atrial fibrillation (AF) are disappointing an

23 hypokalemia and female gender; by contrast, persistent atrial fibrillation (AF) at the time of drug

24 d exercise performance (EP) in patients with persistent atrial fibrillation (AF) converted to sinus r

25 pare catheter ablation with rate control for persistent atrial fibrillation (AF) in heart failure (HF

26 or to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) in patients with hea

27 The success rate of catheter ablation for persistent atrial fibrillation (AF) is still far from sa

28 ng-term successful outcomes with ablation of persistent atrial fibrillation (AF) remains a clinical a

29 The optimal ablation strategy for persistent atrial fibrillation (AF) remains unclear.

30 t atrial tachycardias (AT) in the context of persistent atrial fibrillation (AF) remains undetermined

31 ine 5-year efficacy of catheter ablation for persistent atrial fibrillation (AF) using AF termination

32 In patients with recurrent persistent atrial fibrillation (AF), vulnerability to AF

33 fibrosis are associated with maintenance of persistent atrial fibrillation (AF).

34 ablation is widely used for the treatment of persistent atrial fibrillation (AF).

35 underlying the transition from paroxysmal to persistent atrial fibrillation (AF).

36 o identify drivers in distinct categories of persistent atrial fibrillation (AF).

37 ging (MRI) and atrial electrograms (Egms) in persistent atrial fibrillation (AF).

38 isolation is the cornerstone of ablation for persistent atrial fibrillation (AF).

39 (PVI) is less than optimal in patients with persistent atrial fibrillation (AF).

40 utcome of APVI in patients with long-lasting persistent atrial fibrillation (AF).

41 with a history of paroxysmal (40/66, 61%) or persistent atrial fibrillation and atrial tachyarrhythmi

42 reased in atrial appendages of patients with persistent atrial fibrillation and hearts of decorin nul

43 In 30 patients with persistent atrial fibrillation and left ventricular ejec

44 Here, we expand those observations to persistent atrial fibrillation and severe heart failure.

45 between rotors and fibrosis in patients with persistent atrial fibrillation are mandatory and may inf

46 eter ablation (CA) is commonly performed for persistent atrial fibrillation, but few high-quality ran

47 ng patients with persistent or long-standing persistent atrial fibrillation, but the risk of implanta

48 For patients with persistent atrial fibrillation, CA achieves significantl

49 Ablation of persistent atrial fibrillation can be challenging, often

50 Persistent atrial fibrillation developed in 110 patients

51 ODS AND Thirteen patients with long-standing persistent atrial fibrillation (duration, 12-72 months)

52 In patients with persistent atrial fibrillation, endocardial continuous h

53 PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation [FORWARD]; NCT00597220).

54 contrast, atrial appendages from patients in persistent atrial fibrillation had greater levels of ful

55 Catheter ablation of persistent atrial fibrillation has a lower success rate

56 ion Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure;

57 human model of advanced atrial substrate of persistent atrial fibrillation in heart failure.

58 The hazard ratio for development of persistent atrial fibrillation in patients with dual-cha

59 onization and moderately reduces the risk of persistent atrial fibrillation in patients with sinus-no

60 Pulmonary vein isolation (PVI) for persistent atrial fibrillation is associated with limite

61 term efficacy of catheter-based treatment of persistent atrial fibrillation is unsatisfactory.

62 nt atrial fibrillation (PeAF), long-standing persistent atrial fibrillation (LPeAF), or paroxysmal at

63 icacy of catheter ablation for long-standing persistent atrial fibrillation (LS-AF).

64 tients undergoing electric cardioversion for persistent atrial fibrillation, Mg infusion does not inc

65 n patients with persistent and long-standing persistent atrial fibrillation, no significant differenc

66 The primary endpoint was time to persistent atrial fibrillation or death.

67 d-stage HF patients, in patients with either persistent atrial fibrillation or sinus rhythm.

68 of paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PeAF) with survival, hea

69 n (PAF), 30 patients undergoing ablation for persistent atrial fibrillation (PeAF), and 30 patients u

70 ected "real-world" patients if sources drive persistent atrial fibrillation (PeAF), long-standing per

71 rs and LGE signal intensity in patients with persistent atrial fibrillation (PERS) scheduled for abla

72 Various ablation strategies of persistent atrial fibrillation (PersAF) have had disappo

73 domains appropriately explain long-standing persistent atrial fibrillation physiology at its frequen

74 The underlying mechanisms sustaining human persistent atrial fibrillation (PsAF) is poorly understo

75 xysmal atrial fibrillation or short-standing persistent atrial fibrillation, pulmonary vein (PV) isol

76 In human long-standing persistent atrial fibrillation, rotors potentially expla

77 a potential treatment option for recurrent, persistent atrial fibrillation, significant clinical eva

78 Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study, and the Stroke Pre

79 with symptomatic persistent or long-standing persistent atrial fibrillation, the outcomes of initial

80 ing, which could become an important goal in persistent atrial fibrillation therapy.

81 isolation improves outcomes in patients with persistent atrial fibrillation, there is no benefit of C

82 ts who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (26

83 in Patients With Persistent or Longstanding Persistent Atrial Fibrillation Undergoing Catheter Ablat

84 Eligible patients were adults with persistent atrial fibrillation undergoing planned cardio

85 venty patients (median age, 63.5 years) with persistent atrial fibrillation underwent epicardial thor

86 with symptomatic paroxysmal (n=345; 42%) or persistent atrial fibrillation underwent postprocedural

87 tion at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation), we sought to assess, in

88 60 patients with persistent or long-standing persistent atrial fibrillation who required mitral-valve